What Are The Risk Factors For ImmunityBio Inc. (IBRX)?


As of Friday close, ImmunityBio Inc.’s (NASDAQ:IBRX) stock traded at $1.41. The average number of shares traded per day over the past five days has been 6,116,320 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0300 fall in that time frame. In the last twenty days, the average volume was 4,689,770, while in the previous 50 days, it was 2,977,780.

Since last month, IBRX stock retreated -59.71%. Shares of the company fell to $1.2100 on 03/15/23, the lowest level in the past month. A 52-week high of $7.80 was reached on 01/03/23 after having rallying from a 52-week low of $1.21. Since the beginning of this year, IBRX’s stock price has dropped by -72.19% or -$3.6600, and marked a new high 1 time. However, the stock has declined by -81.92% since its 52-week high.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Financial Health

In the three months ended September 29, ImmunityBio Inc.’s quick ratio stood at 0.30, while its current ratio was 0.30, showing that the company is not able to pay off its debt. Based on annual data, IBRX earned $351.54 million in gross profit and brought in $0.24 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -152.20%. Return on equity (ROE) for the past 12 months was 102.30%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. IBRX’s revenue fell -457.14% to $0.12 million during the quarter, while net income inched up to $70000.0. While analysts expected ImmunityBio Inc. to report -$0.23 quarterly earnings, the actual figure was -$0.28 per share, beating the consensus estimate by -21.70%. During the quarter, the company generated -$64.71 million in EBITDA. The liabilities of ImmunityBio Inc. were 812.18 million at the end of its most recent quarter ended September 29, and its total debt was $714.44 million. The value of shareholders’ equity is $435.84 million.

Technical Picture

This quick technical analysis looks at ImmunityBio Inc.’s (IBRX) price momentum. With a historical volatility rate of 54.94%, the RSI 9-day stood at 10.55% on 17 March.

With respect to its five-day moving average, the current ImmunityBio Inc. price is down by -2.08% percent or -$0.0300. At present, IBRX shares trade -56.35% below its 20-day simple moving average and -73.45% percent below its 100-day simple moving average. However, the stock is currently trading approximately -69.87% below its SMA50 and -62.50% below its SMA200.

Stochastic coefficient K was 14.17% and Stochastic coefficient D was 13.84%, while ATR was 0.2374. Given the Stochastic reading of 14.71% for the 14-day period, the RSI (14) reading has been calculated as 13.70%. As of today, the MACD Oscillator reading stands at -0.0811, while the 14-day reading stands at -0.2948.

Analyst Ratings

Jefferies launched its rating on ImmunityBio Inc. (NASDAQ: IBRX) to a Buy in a note to investors on August 03, 2022. ImmunityBio Inc. (IBRX) has been rated Buy by analysts. According to 0 brokerage firms, IBRX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ImmunityBio Inc. stock as buy, with 1 recommending it as overweight.

With a median target price of $8.00, the current consensus forecast for the stock is $8.00 – $8.00. Based on these forecasts, analysts predict ImmunityBio Inc. (IBRX) will achieve an average price target of $8.00.


Please enter your comment!
Please enter your name here